Study of ASP7374, Cell-culture-derived Influenza Vaccine

Inclusion Criteria: * Healthy or medically stable, as judged on the basis of history and concurrent diseases. * Subject understands procedure of the protocol and is willing to comply with the protocol. * Written informed consent has been obtained. Exclusion Criteria: * Scheduled to receive another vaccine during the study. * Received influenza HA vaccine within 180 days prior to screening. * Received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine. * Diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome. * Received one of the following medications or treatment prior to vaccination with the study vaccine. * Received one of the following medications or treatment prior to vaccination with the study vaccine: Interferon formulation, Drugs which affect the immune system, corticosteroids, G-CSF, M-CSF, Human immunoglobulin products, Blood products, Blood transfusion * History of anaphylactic shock or an allergic reaction such as generalized eruption due to food (including chicken, poultry, foodstuffs derived from chicken, et al.) or drug (including vaccines) allergies, fever ≥39.0°C within 2 days after the previous vaccination (influenza vaccine and others) * History of seizures, except for febrile seizures in childhood